LivaNova PLC Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivaNova PLC on December 7, 2020, covering events occurring on December 2, 2020. The filing details significant changes to the composition and leadership of the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment of Director: Todd Schermerhorn was appointed to the Board, effective December 3, 2020. He brings 35 years of global healthcare experience, including nine years as CFO of C.R. Bard Inc.
- Retirement of Director: Hugh Morrison announced his retirement after the 2021 Annual General Meeting (AGM), concluding five years of service on the LivaNova Board.
- Board Size: The Board will temporarily expand to 11 directors until Mr. Morrison's retirement, after which it will return to 10 directors.
- Leadership Rotations (Effective 2021 AGM):
- Board Chair: Daniel Moore will rotate out of the Chair role; William Kozy will succeed him.
- Audit and Compliance Committee Chair: Todd Schermerhorn will succeed Hugh Morrison.
- Compensation Committee Chair: Stacy Enxing Seng will succeed Dr. Arthur Rosenthal.
Compensation and Governance
Mr. Schermerhorn will receive an annual board retainer fee of $110,000 and a prorated annual service-based restricted stock award with a fair market value of $110,000. The leadership rotations are pursuant to revised Corporate Governance Guidelines recommending rotation after approximately five successive years.
Key Facts for Investor Verification
- Confirm the effective date of William Kozy's succession as Board Chair at the 2021 AGM.
- Verify the specific terms of the restricted stock award granted to Todd Schermerhorn.
- Review the revised Corporate Governance Guidelines to understand the rotation policy for committee chairs.
- Monitor the Board composition to ensure the transition from 11 to 10 directors occurs upon Mr. Morrison's retirement.